ABIVAX to Present Late-Breaking Phase 3 Ulcerative Colitis Data on Oct. 6 at UEG Congress

The detailed eight-week induction results, including outcomes in patients who failed prior advanced therapies, will guide expectations for planned 2026 regulatory submissions.